A.S.S.U.R.E.D. is a truly amazing framework to think about diagnostics.

The Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free, Deliverable to end-users (A.S.S.U.R.E.D.) criteria for point-of-care diagnostics were originally developed in 2003 by the World Health Organization (WHO) to guide affordable test development for resource-limited settings which lacked access to laboratories for population-scale diagnostics.

The A.S.S.U.R.E.D. proposal simplified something the industry had always known but had struggled to articulate: a positive or negative result was not enough. For a diagnostic test to make a difference, it has to identify disease, simply, quickly, reliably, and affordably, for anybody, anywhere. It has to be a test of record, that patients, professionals, and providers can trust and act upon.

Acute respiratory tract infections (RTIs) are placing a massive burden on our healthcare systems, contributing significantly to morbidity and mortality across the world. These infections, encompassing a range of illnesses from the common cold to more severe diseases such as pneumonia and bronchitis, are a leading cause of death worldwide. According to the World Health Organization, respiratory infections account for nearly 4 million deaths annually. This stark statistic highlights the widespread impact of RTIs on individual health and their profound implications for public health systems, which face the dual challenge of managing acute cases and preventing outbreaks. The burden of RTIs necessitates a concerted effort to enhance diagnostic capabilities, improve treatment accessibility, and foster global cooperation in disease surveillance and response.

Antimicrobial resistance threatens not just our healthcare, but modern medicine itself. Discover what needs to happen from better diagnostics to new antibiotics.

PHILADELPHIA, October 4, 2023 (Newswire.com) - Senzo, a life sciences company developing high accuracy, low-cost, point-of-care diagnostic technologies, this week announced an additional $1.8m investment for its breakthrough Amplified Lateral Flow (ALF) test technology, advancing its mission to bring high-quality, affordable tests into the home.

Medscape: Antigen Tests: After Pandemic Success, Time for Bigger Role?

WHERE IS THE DIAGNOSTICS REVOLUTION? Did the pandemic improve diagnostics? Have governments applied the lessons learnt? Has there been a meaningful return on the billions of dollars deployed?

Xtalks Podcast interview with @jeremystackawitz and @vera-kovacevic from the Xtalks show. Everything from the future of diagnostics to the 2023 LifeScience VC landscape.

Senzo and Abingdon Health enter into strategic partnership

Abingdon Health's CDMO service to support Senzo in leveraging its innovative, high-accuracy Amplified Lateral Flow (ALF) point-of-care diagnostics platform technology across multiple product opportunities

SENZO SECURES ADDITIONAL $1.9MM EQUITY FUNDING FOR ITS PCR-ACCURATE LATERAL FLOW TEST

The funding, led by existing investors BioAdvance and Wellness Coaches, follows additional 3rd party studies by University College London and LateralDx, confirming that Senzo's Amplified Lateral Flow (ALF) platform returned greater than 98% accuracy against PCR, including in low viral-load samples

Senzo, a global life sciences company developing high-accuracy, low-cost, point-of-care diagnostic technologies, today announced a partnership with BARDA, part of the Administration for Strategic Preparedness and Response (ASPR), in the US Department of Health and Human Services (HHS) to assist in bringing Senzo's Amplified Lateral Flow (ALF) COVID-19 test in achieving U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) to market.

Biotech company Senzo just raised a $2 million round at a $20 million pre-money valuation to further extend options for lateral flow diagnostics. “Lateral flow,” in this case, is the same type of testing you’ve seen from at-home pregnancy or COVID-19 tests.

Philadelphia-based Senzo, an in-vitro diagnostics company developing innovative, accurate, and accessible testing products, recently raised $2 million in equity funding.

The team, which counts an office in Newtown, recently got results that its at-home tests were as accurate as a PCR test. It aims to bring them to market this year.

Senzo, a Philadelphia-based diagnostic technology company, raised $2 million in an equity funding round to advance its testing platform targeting Covid-19 and other infections.

NEW PODCAST with Jeremy Stackawitz and Duane Mancini, M. Sc. for Project Medtech and Senzo Health discussing the most important themes within diagnostics today including...

Podcast: Jeremy talks to Thomas Hickey from MedTech Gurus on how to translate R&D into product innovation and gets into the 2 fatal errors of product design - essential listening for anybody in Diagnostics Technology.

Ever had to wait five days for a test result, only for it to reveal that (shocker) you need further testing? It didn’t take two years of COVID to see that diagnostics was ripe for disruption.

World's first amplified lateral flow rapid test combines the accuracy and early detection of central lab testing with the simplicity, speed, and low cost of traditional lateral flow tests.

A recent poll of educators conducted by Senzo, a novel rapid testing company, indicates that more accurate COVID-19 at-home tests are needed, and would be beneficial in increasing confidence amongst educators, parents, and students in the ability to minimize the risk of COVID-19 transmission via school attendance, allowing children and educators to better get back to pre-pandemic normal.

COVID-19 RAPID TEST BREAKTHROUGH: SENZO DEVELOPS 7-MINUTE SELF-TEST THAT IS AS ACCURATE AS PCR.